Physician profile
Bennett L Willard
NPI 1134186513
$1,111.71
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $122 · 2021: $152 · 2022: $119 · 2023: $58.68 · 2024: $33.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $91.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $91.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $203.59 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $100.49 | 2019-2020 | |
| Abbott Laboratories | $99.69 | 2019-2024 | Proclaim |
| Assertio Therapeutics, INC. | $98.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $72.93 | 2019 | |
| Collegium Pharmaceutical, INC. | $64.30 | 2019-2023 | Xtampza |
| Vertiflex, INC. | $57.97 | 2019 | |
| Lilly USA, LLC | $55.78 | 2020-2022 | |
| Pfizer INC. | $52.47 | 2019-2024 | |
| Abbvie INC. | $51.92 | 2022-2023 | Qulipta |
| Medtronic USA, INC. | $44.44 | 2019 | |
| Boston Scientific Corporation | $41.25 | 2019-2021 | |
| Amgen INC. | $36.16 | 2019-2021 | |
| Allergan, INC. | $28.04 | 2019 | |
| Nevro Corp. | $27.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $25.55 | 2022 | |
| Grt US Holding, INC. | $20.26 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.24 | 2022 | |
| Biodelivery Sciences International, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bennett Willard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.